Current Listing of The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1-93. (Cancelled).

94. (Previously Presented) A method for treating a mammal suffering from or susceptible to diseases causing apoptosis or apoptosis-like death of cells, except for treatment of immune deficiency, which comprises administering to the mammal a composition comprising ginseng extracts, or ginseng components, its metabolites or salts thereof, wherein doses or dosages of ginseng extracts are adjusted to between 145 pg/kg/day and 1450 μ g/kg/day, and those of ginseng components are adjusted to between 1.67 pg/kg/day and 1.67 mg/kg/day.

95-107. (Cancelled).

108. (Previously Presented) The method according to claim 94, wherein the cells are nerve cells or neurons.

109. (Previously Presented) The method according to claim 108, wherein the diseases causing apoptosis or apoptosis-like death of nerve cells or neurons is cerebral infarction or cerebral apoplexy.

110-116. (Cancelled)

117. (Previously Presented) The method according to any one of claims 94, 108

M. Sakanaka et al U.S.S.N. 10/070,209 Page 3

and 109, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 14.5 μg/kg/day to 1450 μg/kg/day.

- 118. (Previously Presented) The method according to any one of claims 94, 108 and 109, wherein the composition comprises crude saponin fraction and it is administered intravenously in a dose range of 145 pg/kg/day to 145 µg/kg/day.
- 119. (Previously Presented) The method according to any one of claims 94, 108 and 109, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 0.167 µg/kg/day to 1.67 mg/kg/day.
- 120. (Previously Presented) The method according to any one of claims 94, 108 and 109, wherein the composition comprises ginsenoside Rb₁ and it is administered intravenously in a dose range of 1.67pg/kg/day to 1.67mg/kg/day.